Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
Clicks: 6
ID: 302975
2006
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.5
/100
6 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #252 of 432 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV‐1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV‐1 vaccine efficacy trial in Asia.
| Reference Key |
openalex_W2152640863
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Punnee Pitisuttithum, Peter B. Gilbert, Marc Gurwith, William L. Heyward, Michael Martin, Fritz van Griensven, Dale J. Hu, Jordan W. Tappero, Kachit Choopanya |
| Journal | The Journal of infectious diseases |
| Year | 2006 |
| DOI |
10.1086/508748
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.